PUREVAX Feline 3/Rabies 1 YR (0.5 mL)

Company: Boehringer Ingelheim Animal Health

RCP rRabies SWD

Cats

Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Vaccine

Modified Live Virus, Canarypox Vector

PUREVAX Feline 3/Rabies 1 YR (0.5 mL) Indications

This product has been shown to be effective for the vaccination of healthy cats 8 weeks of age and older against feline rhinotracheitis, calici, and panleukopenia viruses, and for the vaccination of healthy cats 12 weeks of age and older against rabies virus. The duration of immunity for rabies is at least one year. The duration of immunity for remaining fractions has not been determined. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.

Description

PureVax^® Feline 3/Rabies contains a nonadjuvanted lyophilized suspension of modified live feline rhinotracheitis, calici, and panleukopenia viruses, recombinant vectored rabies vaccine, plus a sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to rabies. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats.

Directions and dosage: Aseptically rehydrate the lyophilized vaccine with 0.5 mL of the accompanying sterile diluent, and agitate. Administer 1 dose subcutaneously into healthy cats.

For primary vaccination against rabies give 1 dose at or after 12 weeks of age. For primary vaccination against feline rhinotracheitis, calici, and panleukopenia viruses, vaccinate at or after 8 weeks of age and revaccinate with a second dose of this product or PureVax Feline 3, 3 to 4 weeks later. The presence of maternal antibody is known to interfere with the development of active immunity in cats and additional boosters will be required in most young animals. For advice on revaccination frequency, consult your veterinarian. Revaccinate for rabies annually with a single dose.

Precautions

Use entire contents immediately after reconstitution. Contains gentamicin as a preservative. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine. In case of human exposure, contact a physician. Inactivate unused contents before disposal.

Store at 2-8°C (35-46°F). Do not freeze. Do not use chemicals to sterilize syringes and needles. Do not mix with other products, except as specified on the label. Do not vaccinate pregnant cats.

For use in animals only. Restricted to use by or under the direction of a veterinarian.

PUREVAX^® is a registered trademark of the Boehringer Ingelheim Animal Health France SCS, used under license.

Manufactured by:

Boehringer Ingelheim Animal Health USA Inc., Athens, GA 30601 USA

Tel.: 1 (888) 637-4251

VLN/PCN 124/16T9.R0

Distributed in Canada by:

Boehringer Ingelheim Animal Health Canada Inc., Burlington ON L7L 5H4

CPN: 1028376.0